Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
Recently Commenced Full Market Release of X-Twist™ Fixation System, a Cornerstone Product in Anika’s Sports Medicine Portfolio
RevoMotion™ Reverse Shoulder Arthroplasty System Now in Limited Market Release in U.S.
OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System and Tactoset® Injectable Bone Substitute Featured at 2023 AAOS
BEDFORD, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company, today announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration at the 2023 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on March 8-10 in Las Vegas, NV. Throughout the event, Anika will feature the X-Twist Fixation System, the OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System, and Tactoset Injectable Bone Substitute, among its other early intervention orthopedic solutions, in booth #3214.
“We’re thrilled to once again participate in the AAOS 2023 Annual Meeting and have this opportunity to share Anika’s continued commitment to delivering a compelling product portfolio that serves the evolving needs of surgeons across the joint preservation and restoration continuum of care,” said Cheryl R. Blanchard, Ph.D., Anika’s President and CEO. “Anika’s focus will be on our shoulder portfolio including compelling products like X-Twist, Tactoset, and the clinically proven OVOMotion with Inlay Glenoid TSA System, the only system that offers a true inlay glenoid. Furthermore, we continue to bring meaningful new products to market, such as the recent limited market release of our RevoMotion Reverse Shoulder System. These devices are meaningful advancements for surgeons and their patients.”
Dr. Blanchard continued, “The limited launch of RevoMotion is a significant step forward as Anika builds on the strong foundation for our multi-year growth strategy in joint preservation. This is truly a next generation reverse shoulder system, and surgeons are excited about the bone conservation and overall surgical flexibility they get with RevoMotion.”
The X-Twist Fixation System, now in full market release, is a platform of suture anchors designed to be mechanically strong1, easy to use, and support healing. This cornerstone system affords surgeons a variety of knotless and knotted soft tissue fixation options in a single anchor platform. The feature-rich design includes venting intended to support cellular infiltration through the anchor to promote bony ingrowth; a double helix thread that allows fast and easy deployment; the ability to support the surgeon’s preferred combination of multiple sliding suture or tape configurations; and the unique X-Spline™ drive technology which provides more torque transfer for easy anchor insertion.
Tactoset, another featured product, is a calcium phosphate based, hyaluronic acid (HA)-enhanced injectable bone graft substitute. This biocompatible, osteoconductive material is highly flowable, easily injectable, settable, and interdigitates into the trabecular bone architecture and has improved handling characteristics compared to other competitive products.1 While widely used to treat insufficiency fractures, it is now also indicated for use with the augmentation of hardware2, such as suture anchors, which provides greater than twice the pullout strength of nonaugmented anchors by increasing the density of poor-quality bone caused by cysts or osteoporosis.1 It supports placement of anchors in the ideal repair location, eliminating the need for larger or additional anchors or more complex surgical techniques or solutions.
Anika’s clinically-proven OVOMotion with Inlay Glenoid TSA System goes beyond the traditional approach for treating glenohumeral osteoarthritis by offering a reliable, primary solution regardless of glenoid erosion, staging and posterior subluxation.3,4 This TSA System offers the only nonspherical humeral head construct combined with a true Inlay Glenoid implant that is proven to recenter the glenohumeral joint and be 10x more resistant to loosening when compared to onlay glenoid systems.3,4,5 With its now extensive clinical data, this proven primary TSA solution facilitates bone preservation, minimizes blood loss and restores motion without activity restrictions. The unique design preserves and mimics native anatomy while restoring the joint line and reducing the risk of overstuffing the joint, a common issue with other total shoulder systems.
Anika leveraged the compelling design and performance elements of the OVOMotion system to create the RevoMotion Reverse Shoulder Arthroplasty System, a next generation, bone preserving, reverse shoulder system that positions Anika to serve the full spectrum of shoulder replacement procedures.
Key benefits of RevoMotion include:
- Industry’s smallest diameter threaded glenoid baseplate
- Simplified component insertion
- Bone preservation and patient personalization
- Enhanced efficiency for surgeons and facilities with two streamlined instrument trays
RevoMotion will be shown during the AAOS at the Anika booth by appointment only due to its limited market release status.
There will be multiple opportunities throughout the 2023 AAOS Annual Meeting in Las Vegas to learn more about Anika’s compelling products at the Anika booth, #3214, as well as during two Innovation Theater sessions held in booth #6643:
The first Innovation Theater session:
- “A Paradigm Shift: The New Standard in Total Shoulder Arthroplasty,” presented by Anthony Miniaci, MD, an orthopedic surgeon at Baptist Health Florida, will discuss the now extensive collection of data, clinical insights, and why surgeons are adopting the OVOMotion with Inlay Glenoid System as their primary TSA.
- 9:30 AM on Wednesday, March 8th in booth #6643
The second Innovation Theater session:
- “The Inlay Glenoid: Addressing B2 Glenoids - Inset ≠ Inlay,” also led by Anthony Miniaci, MD, will highlight the Inlay Glenoid and the data surrounding the data and use of a true Inlay Glenoid
- 10:00 AM on Thursday, March 9th in booth #6643.
About Anika
(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine, and bone preserving joint technologies, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit
ANIKA, ANIKA THERAPEUTICS, OVOMOTION, REVOMOTION, TACTOSET, X-SPLINE, X-TWIST, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries.
References
1 Data on file, Anika Therapeutics, Inc.
2 Tactoset Instructions for Use. Anika Therapeutics, Inc., AML 500-335
3 Gagliano JR, Helms SM, Colbath GP, Przestrzelski BT, Hawkins RJ, DesJardins JD. A comparison of onlay versus inlay glenoid component loosening in total shoulder arthroplasty. J Shoulder Elbow Surg. 2017 Jul;26(7):1113-1120. doi: 10.1016/j.jse.2017.01.018. Epub 2017 Mar 27. PMID: 28359697.
4 Total shoulder arthroplasty with nonspherical humeral head and inlay glenoid replacement: clinical results comparing concentric and nonconcentric glenoid stages in primary shoulder arthritis. Miniaci, Anthony et al., JSES Open Access, Volume 0, Issue 0
5 Sercan Yalcin, Michael Scarcella, Anthony Miniaci, Does non-spherical humeral head with inlay glenoid re-center the glenohumeral joint? Seminars in Arthroplasty: JSES, Volume 31, Issue 2, 2021, Pages 310-316, ISSN 1045-4527
Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; and (x) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at . Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
For Media Inquiries:
Greenough
Christine Williamson, 617-922-1289
Senior Vice President
